keyword
MENU ▼
Read by QxMD icon Read
search

breast neoadjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28535650/-texture-analysis-based-on-contrast-enhanced-mri-can-predict-treatment-response-to-neoadjuvant-chemotherapy-of-breast-cancer
#1
S H Sun, C W Zhou, L Y Zhao, R Z Zhang, H Ouyang
Objective: To investigate whether texture analysis based on contrast-enhanced MRI can predict pathological complete response of locally advanced breast cancer undergoing neoadjuvant chemotherapy(NAC). Methods: Forty-seven patients with breast cancer undergone neoadjuvant chemotherapy from January 2015 to February 2016 were divided into pathological complete response (pCR) group or non-pathological complete response (non-pCR) group based on surgical pathology. Their parameters of texture analysis based on MRI before neoadjuvant chemotherapy and after 2 cycles of treatment were analyzed...
May 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28532642/optical-mammography-in-patients-with-breast-cancer-undergoing-neoadjuvant-chemotherapy-individual-clinical-response-index
#2
Pamela G Anderson, Sirishma Kalli, Angelo Sassaroli, Nishanth Krishnamurthy, Shital S Makim, Roger A Graham, Sergio Fantini
RATIONALE AND OBJECTIVES: We present an optical mammography study that aims to develop quantitative measures of pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Such quantitative measures are based on the concentrations of oxyhemoglobin ([HbO2]), deoxyhemoglobin ([Hb]), total hemoglobin ([HbT]), and hemoglobin saturation (SO2) in breast tissue at the tumor location and at sequential time points during chemotherapy. MATERIALS AND METHODS: Continuous-wave, spectrally resolved optical mammography was performed in transmission and parallel-plate geometry on 10 patients before treatment initiation and at each NAC administration (mean number of optical mammography sessions: 12, range: 7-18)...
May 19, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28531188/monitoring-tumor-response-to-neoadjuvant-chemotherapy-using-mri-and-18f-fdg-pet-ct-in-breast-cancer-subtypes
#3
Alexander M Th Schmitz, Suzana C Teixeira, Kenneth E Pengel, Claudette E Loo, Wouter V Vogel, Jelle Wesseling, Emiel J Th Rutgers, Renato A Valdés Olmos, Gabe S Sonke, Sjoerd Rodenhuis, Marie Jeanne T F D Vrancken Peeters, Kenneth G A Gilhuijs
PURPOSE: To explore guidelines on the use of MRI and PET/CT monitoring primary tumor response to neoadjuvant chemotherapy (NAC), taking breast cancer subtype into account. MATERIALS AND METHODS: In this prospective cohort study, 188 women were included with stages II and III breast cancer. MRI and 18F-FDG-PET/CT were acquired before and during NAC. Baseline pathology was assessed from tumor biopsy. Tumors were stratified into HER2-positive, ER-positive/HER2-negative (ER-positive), and ER-negative/PR-negative/HER2-negative (triple-negative) subtypes, and treated according to subtype...
2017: PloS One
https://www.readbyqxmd.com/read/28527420/factors-predictive-of-locoregional-recurrence-following-neoadjuvant-chemotherapy-in-patients-with-large-operable-or-locally-advanced-breast-cancer-an-analysis-of-the-eortc-10994-big-1-00-study
#4
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines...
May 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28526187/chemotherapy-may-eradicate-ductal-carcinoma-in-situ-dcis-but-not-the-associated-microcalcifications
#5
H Goldberg, J Zandbank, V Kent, M Leonov-Polak, A Livoff, A Chernihovsky, M Guindy, E Evron
INTRODUCTION: We studied the effect of neoadjuvant chemotherapy (NAC) ± trastuzumab on the ductal carcinoma in situ (DCIS) component in patients with locally advanced breast cancer who achieved pathological complete response (pCR). METHODS: The diagnostic biopsies of 92 consecutive breast cancer patients that were treated with neoadjuvant chemotherapy (NAC) ± trastuzumab were evaluated for the presence of DCIS. Upon completion of NAC, the surgical specimens were evaluated for complete eradication of both the invasive and non-invasive cancer in the breast...
May 4, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28525810/tumor-infiltrating-lymphocytes-in-patients-with-her2-positive-breast-cancer-treated-with-neoadjuvant-chemotherapy-plus-trastuzumab-lapatinib-or-their-combination-a-meta-analysis-of-randomized-controlled-trials
#6
REVIEW
C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, D Fumagalli, E de Azambuja, R Salgado, C Sotiriou, K Willard-Gallo, M Ignatiadis
BACKGROUND: A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the association between baseline TIL and pathologic complete response (pCR) rates in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab and lapatinib either alone or in combination...
May 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28525534/lymphocyte-density-determined-by-computational-pathology-validated-as-a-predictor-of-response-to-neoadjuvant-chemotherapy-in-breast-cancer-secondary-analysis-of-the-artemis-trial
#7
H R Ali, A Dariush, J Thomas, E Provenzano, J Dunn, L Hiller, A-L Vallier, J Abraham, T Piper, J M S Bartlett, D A Cameron, L Hayward, J D Brenton, P D P Pharoah, M Irwin, N A Walton, H M Earl, C Caldas
Background: HASH(0x3c49e60) Patients and methods: HASH(0x30703c0) Results: HASH(0x337f788) Conclusions: HASH(0x343bf48)
May 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28523352/interim-heterogeneity-changes-measured-using-entropy-texture-features-on-t2-weighted-mri-at-3-0%C3%A2-t-are-associated-with-pathological-response-to-neoadjuvant-chemotherapy-in-primary-breast-cancer
#8
Shelley Henderson, Colin Purdie, Caroline Michie, Andrew Evans, Richard Lerski, Marilyn Johnston, Sarah Vinnicombe, Alastair M Thompson
OBJECTIVES: To investigate whether interim changes in hetereogeneity (measured using entropy features) on MRI were associated with pathological residual cancer burden (RCB) at final surgery in patients receiving neoadjuvant chemotherapy (NAC) for primary breast cancer. METHODS: This was a retrospective study of 88 consenting women (age: 30-79 years). Scanning was performed on a 3.0 T MRI scanner prior to NAC (baseline) and after 2-3 cycles of treatment (interim)...
May 18, 2017: European Radiology
https://www.readbyqxmd.com/read/28521821/intratumoral-and-peritumoral-radiomics-for-the-pretreatment-prediction-of-pathological-complete-response-to-neoadjuvant-chemotherapy-based-on-breast-dce-mri
#9
Nathaniel M Braman, Maryam Etesami, Prateek Prasanna, Christina Dubchuk, Hannah Gilmore, Pallavi Tiwari, Donna Pletcha, Anant Madabhushi
BACKGROUND: In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). METHODS: A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases...
May 18, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#10
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28507762/circulating-tumor-cell-clusters-associated-gene-plakoglobin-is-a-significant-prognostic-predictor-in-patients-with-breast-cancer
#11
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Tsutomu Takashima, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: Circulating tumor cells (CTCs) are linked to metastatic relapse and are regarded as a prognostic marker for human cancer. High expression of plakoglobin, a cell adhesion protein, within the primary tumor is positively associated with CTC clusters in breast cancer. In this study, we investigated the correlation between plakoglobin expression and survival of breast cancer. METHODS: We evaluated 121 breast cancer patients treated with neoadjuvant chemotherapy...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28488142/a-prospective-randomized-controlled-trial-of-hydrating-nail-solution-for-prevention-or-treatment-of-onycholysis-in-breast-cancer-patients-who-received-neoadjuvant-adjuvant-docetaxel-chemotherapy
#12
Ji-Yeon Kim, Oh Nam Ok, Jeong-Ju Seo, Soo-Hyeon Lee, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
PURPOSE: Onycholysis and other nail toxicities occur in approximately 20-30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients' quality of life. In this study, we aimed to evaluate the efficacy of hydrating nail solution (HNS) (EVONAIL(®) solution, Evaux Laboratories, France) for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities. METHODS: This study was a prospective, randomized, controlled study of HNS for the prevention or treatment of onycholysis in patients with docetaxel after doxorubicin plus cyclophosphamide...
May 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28487444/the-longitudinal-transcriptional-response-to-neoadjuvant-chemotherapy-with-and-without-bevacizumab-in-breast-cancer
#13
Laxmi Silwal-Pandit, Silje Nord, Hedda von der Lippe Gythfeldt, Elen K Møller, Thomas Fleischer, Einar Rødland, Marit Krohn, Elin Borgen, Øystein Garred, Tone Olsen, Phuong Vu, Helle Skjerven, Anne Fangberget, Marit M Holmen, Ellen Schlichting, Elisabeth Wille, Mette Nordberg Stokke, Hans Kristian Moen Vollan, Vessela N Kristensen, Anita Langerød, Steinar Lundgren, Erik A Wist, Bjørn Naume, Ole Christian Lingjerde, Anne-Lise Borresen-Dale, Olav Engebraaten
Chemotherapy induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase II clinical trial to assess the effect of neoadjuvant chemotherapy with the addition of bevacizumab. <br />Experimental Design: Tumor biopsies and whole-transcriptome mRNA profiles were obtained at three fixed time points with 66 patients in each arm.  Altogether, 358 specimens from 132 patients were available, representing the transcriptional state before treatment start, at 12 weeks and after treatment (25 weeks)...
May 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28487053/a-novel-less-invasive-approach-for-axillary-staging-after-neoadjuvant-chemotherapy-in-patients-with-axillary-node-positive-breast-cancer-by-combining-radioactive-iodine-seed-localization-in-the-axilla-with-the-sentinel-node-procedure-risas-a-dutch-prospective
#14
Thiemo J A van Nijnatten, Janine M Simons, Marjolein L Smidt, Carmen C van der Pol, Paul J van Diest, Agnes Jager, David van Klaveren, Boen L R Kam, Marc B I Lobbes, Maaike de Boer, Kees Verhoef, Linetta B Koppert, Ernest J T Luiten
BACKGROUND: In 1 of 3 patients with initial lymph node-positive (cN(+)) breast cancer, neoadjuvant chemotherapy (NAC) results in an axillary pathologic complete response (ax-pCR). This urges the need for a less-invasive axillary staging method. Recently introduced less-invasive procedures have been insufficient in accurately identifying ax-pCR. Therefore, we propose a novel less-invasive axillary staging procedure: the Radioactive Iodine Seed localization in the Axilla with the Sentinel node procedure (RISAS), a combination of the procedure of marking axillary lymph nodes with radioactive iodine seeds (MARI) and sentinel lymph node biopsy (SLNB)...
April 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28484921/preoperative-prediction-of-node-negative-disease-after-neoadjuvant-chemotherapy-in-patients-presenting-with-node-negative-or-node-positive-breast-cancer
#15
Brittany L Murphy, Tanya L Hoskin, Courtney Day N Heins, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: Axillary node status after neoadjuvant chemotherapy (NAC) influences the axillary surgical staging procedure as well as recommendations regarding reconstruction and radiation. OBJECTIVE: Our aim was to construct a clinical preoperative prediction model to identify the likelihood of patients being node negative after NAC. METHODS: Using the National Cancer Database (NCDB) from January 2010 to December 2012, we identified cT1-T4c, N0-N3 breast cancer patients treated with NAC...
May 8, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28484222/in-silico-evaluation-of-dna-damage-inducible-transcript-4-gene-ddit4-as-prognostic-biomarker-in-several-malignancies
#16
Joseph A Pinto, Christian Rolfo, Luis E Raez, Alexandra Prado, Jhajaira M Araujo, Leny Bravo, Williams Fajardo, Zaida D Morante, Alfredo Aguilar, Silvia P Neciosup, Luis A Mas, Denisse Bretel, Justin M Balko, Henry L Gomez
DDIT4 gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several in vitro studies indicate that its expression favors cancer progression. We have previously described that DDIT4 expression is an independent prognostic factor for tripe negative breast cancer resistant to neoadjuvant chemotherapy. We herein report that high DDIT4 expression is related to the outcome (recurrence-free survival, time to progression and overall survival) in several cancer types. We performed in silico analysis in online platforms, in pooled datasets from KM Plotter and meta-analysis of individual datasets from SurvExpress...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28484211/metabolic-radiomics-for-pretreatment-18-f-fdg-pet-ct-to-characterize-locally-advanced-breast-cancer-histopathologic-characteristics-response-to-neoadjuvant-chemotherapy-and-prognosis
#17
Seunggyun Ha, Sohyun Park, Ji-In Bang, Eun-Kyu Kim, Ho-Young Lee
Radiomics has been spotlighted as imaging biomarker for estimation of intratumoral heterogeneity (ITH) which is regarded as the main reason for resistance to tumor treatment. Although a number of studies has shown clinical evidences that separate measurement of metabolic ITH by texture features (TFs) on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) has prognostic ability in various tumors, there has been no consensus regarding the best parameter representing ITH...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28484080/neoadjuvant-chemotherapy-increases-rates-of-breast-conserving-surgery-in-early-operable-breast-cancer
#18
V Cm Man, P Sy Cheung
INTRODUCTION: Neoadjuvant chemotherapy is commonly used in stage III breast cancer for disease down-staging. Its use has now been extended to early breast cancer to increase the rate of breast-conserving surgery. This study aimed to evaluate the effectiveness of neoadjuvant chemotherapy in early operable cancers. METHODS: A retrospective study was carried out at the Hong Kong Sanatorium & Hospital of 102 patients with stage I to III primary breast cancer. All patients who underwent neoadjuvant chemotherapy followed by definitive breast surgery between January 2004 and July 2013 were included...
May 9, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28481792/multiparametric-evaluation-of-treatment-response-to-neoadjuvant-chemotherapy-in-breast-cancer-using-integrated-pet-mr
#19
Jane Wang, Tiffany Ting-Fang Shih, Ruoh-Fang Yen
PURPOSE: The aim of this study was to investigate whether integrated PET/MR system can predict the treatment response to neoadjuvant chemotherapy (NAC) early in the course of breast cancer treatment. METHODS: Fourteen women with newly diagnosed invasive breast cancer (median age, 54.5 years) were recruited. Each participant underwent 2 PET/MR studies. Study 1 was pre-NAC; study 2 was early in NAC treatment (after the first or second cycle). PET parameters included SUVmax and total lesion glycolysis (TLG)...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28481705/breast-reconstruction-with-postmastectomy-radiation-choices-and-tradeoffs
#20
Matthew M Poppe, Jayant P Agarwal
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
May 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
55508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"